Enrollment Completed in Phase 2 ALLSTAR Cardiac Clinical Trial
Enrollment Completed in Phase 2 ALLSTAR Cardiac Clinical Trial
Capricor Therapeutics Inc. has announced the completion of patient enrollment in their Phase 2 ALLSTAR clinical trial. ALLSTAR stands for ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration, and this trial will test Capricor’s CAP-1002 product in patients suffering from cardiac dysfunction following a heart attack. CAP-1002 cells are cardiosphere derived cells (CDCs) that were…
View On WordPress











